CPT code 68841 denotes the insertion of a controlled-release drug implant into the lacrimal ducts, with optional dilation of the duct, to manage ocular inflammation, glaucoma, or related conditions. This targeted, sustained-delivery approach can reduce the need for frequent topical dosing and may alter clinical workflows for ophthalmology practices and ambulatory surgical centers. Nationally, procedures using lacrimal duct drug-delivery implants are of interest for their clinical implications in chronic eye disease management and for payers assessing coverage of novel sustained-release devices.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what CPT code 68841 represents, typical sites of service, and the clinical context for use. The publication summarizes coverage and billing considerations across major payers, highlights common billing modifiers and coding practices where applicable, and provides benchmark references and policy updates relevant to sustained ocular drug-delivery implants. The content is intended to support coding staff, practice managers, and policy analysts in understanding the code’s clinical purpose and administrative implications at a national level.

Data not available in the input: associated taxonomies, specific ICD-10 diagnoses, payer-specific coverage rules, and related codes.